trending Market Intelligence /marketintelligence/en/news-insights/trending/jIG790lSWzcADXRU0TovLQ2 content esgSubNav
In This List

Roche again extends tender offer to acquire Spark Therapeutics for $4.3B

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Roche again extends tender offer to acquire Spark Therapeutics for $4.3B

Roche Holding AG is again extending the tender offer period to acquire all shares of Spark Therapeutics Inc. at $114.50 each, or $4.3 billion in total.

The offer will now expire at 5 p.m. ET on Oct. 30, unless further extended. Previously, it was announced that the tender offer would expire at 5 p.m. ET on Oct. 1.

Basel, Switzerland-based Roche and Philadelphia-based Spark said the move will provide additional time for the U.S. Federal Trade Commission and the U.K. Competition and Markets Authority to complete their review of the deal.

As of 5 p.m. New York City time on Sept. 27, about 8,251,571 shares had been tendered to Roche's offer, representing roughly 21.4% of Spark's outstanding shares.

Roche has already extended the offer period several times from the initial April 3 deadline.

MacKenzie Partners Inc. is acting as information agent for the tender offer. Citibank NA is the depository for the offer.